<article>Beijing-based biotech company <a href="https://www.dealstreetasia.com/?s=EdiGene+Inc" target="_blank" rel="noopener">EdiGene Inc</a> &#8211; that uses genome editing technologies for novel therapeutics and advanced drug discovery solutions &#8211; has raised about $15 million in a pre-Series B financing round led by <a href="https://www.dealstreetasia.com/?s=Lilly+Asia+Ventures+" target="_blank" rel="noopener">Lilly Asia Ventures </a>(LAV) a venture capital firm from Shanghai, according to an announcement.
Beijing-based investment firm Huagai Capital also participated in this round.</article>

Beijing-based biotech company <a href="https://www.dealstreetasia.com/?s=EdiGene+Inc" target="_blank" rel="noopener">EdiGene Inc</a> &#8211; that uses genome editing technologies for novel therapeutics and advanced drug discovery solutions &#8211; has raised about $15 million in a pre-Series B financing round led by <a href="https://www.dealstreetasia.com/?s=Lilly+Asia+Ventures+" target="_blank" rel="noopener">Lilly Asia Ventures </a>(LAV) a venture capital firm from Shanghai, according to an announcement.
Beijing-based investment firm Huagai Capital also participated in this round.
Established in 2015, EdiGene’s Series A round was led by IDG Capital with participation from Wi Harper Group and others.
“This investment will allow us to continue advancing our promising portfolio of therapeutic programs based on gene-editing technologies,” said Dr. Dong Wei, CEO of EdiGene.
Genome editing technology is considered as one of the most promising healthcare innovations. EdiGene aims to use the technology to repair defective genetic material that causes diseases and create solutions to advance drug discovery.
EdiGene was founded by Wensheng Wei, a professor in Peking University who also is the vice director of Chinese Association of Genome Editing.
The company has subsidiaries in Guangzhou, China and Cambridge, USA.
“We will continue to further develop our proprietary high throughput genome screening platforms into a comprehensive solution for our partners in key areas such as drug sensitivity, drug resistance and synthetic lethality,” said Wei.
Dr. Dong Wei was appointed as the chief executive officer of the company in early August. The appointment comes at a time when EdiGene aims to grow into the next stage of its therapeutic pipeline and drug discovery service.
Also Read:
<a style="color: #ff0000;" href="https://www.dealstreetasia.com/stories/impact-therapeutics-decheng-capital-104166/">Impact Therapeutics raises $30m in Decheng Capital-led Series C round</a>
<a style="color: #ff0000;" href="https://www.dealstreetasia.com/stories/temasek-hangzhou-just-biotherapeutics-99328/">Temasek-backed Hangzhou Just Biotherapeutics closes $35m Series B+ round</a>
<a style="color: #ff0000;" href="https://www.dealstreetasia.com/stories/temasek-china-biotech-innovent-96927/">Temasek backs Chinese biotech firm Innovent’s $150m Series E</a>
&nbsp;

Chinese biotech EdiGene raises $15m pre-Series B led by Lilly Asia Ventures

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief

Chinese biotech EdiGene raises $15m pre-Series B led by Lilly Asia Ventures

Create an account to continue reading this premium story for free

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief